OBP Ondine Biomed

 
TIDMOBP 
 
Issue of Equity 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
April 13, 2010 
 
Ondine Biopharma Announces Share Issuance 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 13, 2010) - 
 
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 
 
Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the "Company"), a medical technology company 
developing photodisinfection based products, today announced it has issued 947,688 common shares at a 
price of $0.12 per share to an arms length party as consideration for and in settlement of past 
advisory services provided to the Company. The shares are subject to a regulatory hold period in 
Canada which expires on August 13, 2010. Application has been made for these shares to be admitted to 
trading on AIM and dealings are expected to commence on April 16, 2010. 
 
This press release does not constitute an offer to sell or a solicitation of an offer to sell any of 
the securities in the United States. The securities have not been and will not be registered under the 
U.S. Securities Act or any state securities laws and may not be offered or sold within the United 
States unless registered under the U.S. Securities Act and applicable state securities laws or an 
exemption from such registration is available. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, 
fungal and viral infections. The Company is focused on developing leading edge products utilizing its 
patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy 
without encouraging the formation and spread of antibiotic resistance. The Company is based in 
Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, 
Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebiopharma.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", 
"expect" and other similar expressions, are forward-looking statements that involve a number of risks 
and uncertainties. Factors that could cause actual results to differ materially from those projected 
in the Company's forward-looking statements include the following: market acceptance of our 
technologies and products; our ability to obtain financing; our financial and technical resources 
relative to those of our competitors; our ability to keep up with rapid technological change; 
government regulation of our technologies; our ability to enforce our intellectual property rights and 
protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the 
timing of commercial product launches; the ability to achieve key technical milestones in key products 
and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Ryan Gaffney 
Nominated Adviser 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of 
this release. 
 
 
Ondine Biopharma Corporation 
 

Ondine Biomed (LSE:OBP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

Ondine Biomed (LSE:OBP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024